AIP与2型糖尿病及相关疾病关系的研究进展

Research Progress on the Relationship between AIP and Type 2 Diabetes Mellitus and Related Diseases

许多生物标志物被国内外学者发现并应用于临床,而选择一种简单且容易测定的生物标志物用来评估并预测疾病的风险则显得尤为重要。血浆动脉粥样硬化指数(Atherogenic Index of Plasma,AIP)是一种创新性新型生物标志物,其值是由甘油三酯与高密度脂蛋白-胆固醇的摩尔浓度对数转换比率组成。本综述通过对AIP作基本概括及其脂代谢的相关机制,了解到AIP作为一种新型综合生物标志物,对2型糖尿病及其并发症以及对相关疾病比如动脉粥样硬化性心血管疾病、非酒精性脂肪性肝病、代谢综合征等疾病具有很好的预测及风险评估能力。本文重点分析AIP与2型糖尿病、2型糖尿病大血管病变以及肾脏病变之间的关联,探索AIP作为新型生物标志物的研究潜力,以期为上述疾病的预防和治疗提供一种诊疗思路和研究方向。

Many biomarkers have been discovered and applied to clinical practice by scholars at home and abroad,and it is particularly important to choose a simple and easily measured biomarker to assess and predict the risk of dis-ease.The atherogenic index of plasma(AIP)is an innovative new biomarker,whose value is composed of the ratio of molar concentration logarithm conversion of triglyceride to high-density lipoprotein-cholesterol.In this review,AIP was considered as a novel comprehensive biomarker through a basic overview of AIP and its related mechanisms of lipid metabolism.It has a good ability to predict and assess the risk of type 2 diabetes mellitus and its complications,as well as related diseases such as atherosclerotic cardiovascular disease,non-alcoholic fatty liver disease,metabolic syndrome and other diseases.This paper focused on the analysis of the association between AIP and type 2 diabetes mellitus,type 2 diabetes macrovascular disease and kidney disease,and explored the research potential of AIP as a new biomarker,with a view to providing a diagnosis and treatment idea and research direction for the prevention and treatment of these diseases.